Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
US5006526A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 17, 1988 |
| Grant date | Apr 9, 1991 |
| Priority date | — |
| Expiry date | Oct 17, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the treatment of conditions associated with atherosclerosis in vertebrate animals, particularly man. A prolactin-inhibiting compound administered to the animal exhibiting the atherosclerotic conditions, in dosage sufficient to decrease the total plasma cholesterol and total triglyceride levels, will over a sufficient period of time suppress atherosclerosis and reduce lipid plaques in the walls of the blood vessels of the animal. Exemplary of prolactin-inhibiting compounds are the ergot-related drugs 2-bromo-alpha-ergocryptine, 6-methyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline, 1,6-dimethyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline, 8-acylaminoergolenes, ergocornine, 9,10-dihydroergocornine, and D-2-halo-6-alkyl-8-substituted ergolines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.